Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16111768 | 0.88 | L3MBTL1 (0.47) | MTNR1AMTNR1BL3MBTL1KMT2AMEN1 | |
| SCHEMBL18200159 | 0.87 | MTNR1A (0.42) | MTNR1AMTNR1BL3MBTL1GAAKMT2A | |
| SCHEMBL9791378 | 0.86 | ELANE (0.46) | MTNR1AMTNR1BGAAKMT2AHPGD | |
| SCHEMBL16046006 | 0.80 | KMT2A (0.46) | L3MBTL1KMT2AMEN1ATMHPGD | |
| SCHEMBL14087507 | 0.77 | ESR1 (0.47) | L3MBTL1GAAKMT2AMEN1ATM | |
| SCHEMBL16072692 | 0.77 | SRC (0.54) | KMT2AMEN1HPGDELANENFE2L2 | |
| SCHEMBL2221010 | 0.76 | ELANE (0.49) | KMT2AHPGDELANENFE2L2ALDH1A1 | |
| SCHEMBL95873 | 0.76 | ALDH1A1 (0.53) | L3MBTL1GAAKMT2AMEN1ATM | |
| SCHEMBL18189126 | 0.75 | KDM4E (0.44) | L3MBTL1GAAKMT2AMEN1ATM | |
| SCHEMBL29391949 | 0.75 | CA12 (0.48) | MTNR1AMTNR1BL3MBTL1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026044053-A1 | SMALL MOLECULE TARGETING OF FUSED IN SARCOMA (FUS) AND USES THEREOF | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2026-02-26 | — | — | WO | disclosed |
| US-9920029-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920029-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-03-20 | — | — | US | disclosed |
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | MUSC Foundation for Research Development (10 pp.) | 2015-08-06 | — | — | US | disclosed |
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | MUSC Foundation for Research Development (10 pp.) | 2015-08-06 | — | — | US | disclosed |
| US-9079853-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079853-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | CLN6, AREG, HASPIN | MTNR1A 639/4885MTNR1B 314/4885L3MBTL1 2692/4885 |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | CLN6, AREG, HASPIN | MTNR1A 639/4885MTNR1B 314/4885L3MBTL1 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.